Xenon Pharmaceuticals (XENE) Tops Q2 EPS by 24c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 4:02 PM EDTXEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported its financial results for second quarter ended June 30, 2020 and provided a corporate update.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, Xenon continues to manage well as we respond to the global impacts of the COVID-19... More
